Nothing Special   »   [go: up one dir, main page]

Miale et al., 1969 - Google Patents

Prothrombin Time Standardization: Proposal of the Standards Committee, College of American Pathologists, Subcommittee on Coagulation Reagents

Miale et al., 1969

Document ID
8022842373863491298
Author
Miale J
LaFond D
Kent J
Garcia A
Publication year
Publication venue
American Journal of Clinical Pathology

External Links

Snippet

Standard plasmas having a known concentration of the coagulation factors determining the one-stage prothrombin time are evaluated from the standpoint of factor assays, stability, and reproducibility. The problem of standardizing the one-stage test and commercial …
Continue reading at academic.oup.com (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/04—Phospholipids, i.e. phosphoglycerides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases

Similar Documents

Publication Publication Date Title
Van den Besselaar et al. Multicenter evaluation of a new capillary blood prothrombin time monitoring system
Miale et al. Prothrombin Time Standardization: Proposal of the Standards Committee, College of American Pathologists, Subcommittee on Coagulation Reagents
Tripodi et al. Position Paper on laboratory testing for patients on direct oral anticoagulants. A Consensus Document from the SISET, FCSA, SIBioC and SIPMeL
Douxfils et al. Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays
Loeliger et al. Questions and answers on prothrombin time standardisation in oral anticoagulant control
Estivals et al. Prothrombin fragment 1+ 2, thrombin–antithrombin III complexes and D‐dimers in acute deep vein thrombosis: effects of heparin treatment
Furie et al. Randomized prospective trial comparing the native prothrombin antigen with the prothrombin time for monitoring oral anticoagulant therapy
Nsiri et al. Abnormalities of coagulation and fibrinolysis in homozygous sickle cell disease
WO1991001383A1 (en) Method for diagnosing blood clotting disorders
WO2002079375A1 (en) Rapid assessment of coagulation activity in whole blood
Duchemin et al. A new assay based on thrombin generation inhibition to detect both protein C and protein S deficiencies in plasma
Hall Erythrocyte dynamics in liver disease
de Gennesb et al. Plasma factor VII, triglyceride concentration and fibrin degradation products in primary hyperlipidemia: a clinical and laboratory study
Dati et al. Multicenter evaluation of a chromogenic substrate method for photometric determination of prothrombin time
Greenway et al. Point-of-care monitoring of oral anticoagulation therapy in children
Van Wijk et al. Mechanized amidolytic technique for determination of factor X and factor-X antigen, and its application to patients being treated with oral anticoagulants.
Palareti et al. Oral anticoagulant therapy control: Evidence that INR expression improves the inter-laboratory comparability of results-The Bologna oral anticoagulant control exercise
EP0406971B1 (en) Method and kit for determining the functional activity of protein S in human plasma
Tardy et al. Effects of long travels in sitting position in elderly volunteers on biological markers of coagulation activation and fibrinolysis
Szczeklik et al. Delayed generation of thrombin in clotting blood of atopic patients with hayfever and asthma
Poller Prothrombin time (PT)
Pizzoleo et al. Haemostatic variables in arterial hypertension
Greenberg et al. Evaluation of preanalytical variables associated with measurement of prothrombin fragment 1.2
KR20020042539A (en) Method and apparatus for presenting thrombosis and hemostasis assay data
JPH07270406A (en) Synthetic phospholipid reagent